Andarine | GTx-007 | CAS#401900-40-1 | selective androgen receptor modulator | SARM

MedKoo Cat#: 319520 | Name: Andarine

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Andarine, also known as GTx-007 and S-4, is an investigational selective androgen receptor modulator (SARM) for treatment of conditions such as muscle wasting, osteoporosis and benign prostatic hypertrophy. Andarine is an orally active partial agonist for androgen receptors. It is less potent in both anabolic and androgenic effects than other SARMs. In an animal model of benign prostatic hypertrophy, andarine was shown to reduce prostate weight with similar efficacy to finasteride, but without producing any reduction in muscle mass or anti-androgenic side effects.

Chemical Structure

Andarine

CAS#401900-40-1

Theoretical Analysis

MedKoo Cat#: 319520

Name: Andarine

CAS#: 401900-40-1

Chemical Formula: C19H18F3N3O6

Exact Mass: 441.1148

Molecular Weight: 441.36

Elemental Analysis: C, 51.71; H, 4.11; F, 12.91; N, 9.52; O, 21.75

Price and Availability

Size	Price	Availability
1g	USD 150.00	Ready to ship
2g	USD 250.00	Ready to ship
5g	USD 450.00	Ready to ship
10g	USD 750.00	Ready to ship
20g	USD 1,350.00	Ready to ship
50g	USD 2,950.00	Ready to ship

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

No Data

Synonym

GTx-007; GTx007; GTx 007; S-4; S4; S 4; Andarine

IUPAC/Chemical Name

(2S)-3-(4-acetamido-phenoxy)-2-hydroxy-2-methyl-N-(4-nitro-3-trifluoromethyl-phenyl)-propionamide

InChi Key

YVXVTLGIDOACBJ-SFHVURJKSA-N

InChi Code

InChI=1S/C19H18F3N3O6/c1-11(26)23-12-3-6-14(7-4-12)31-10-18(2,28)17(27)24-13-5-8-16(25(29)30)15(9-13)19(20,21)22/h3-9,28H,10H2,1-2H3,(H,23,26)(H,24,27)/t18-/m0/s1

SMILES Code

O=C(NC1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1)[C@@](C)(O)COC2=CC=C(NC(C)=O)C=C2

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO, not in water

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Product Data

Product Data

Certificate of Analysis

View CoA: current batch, Lot#CRB60921

QC Data

View QC data: current batch, Lot#CRB60921

Safety Data Sheet (SDS)

View Safety Data Sheet (SDS)

Instruction

View handling instruction

Biological target:

GTx-007 (S-4) is a nonsteroidal androgen receptor (AR) modulator (SARM) and a partial agonist, with Ki of 4 nM.

In vitro activity:

N/A

In vivo activity:

Whole body BMD measured by DEXA at day 120 is presented in Table II. As expected, the BMD in OVX rats (0.197 g/cm2) was significantly less than that observed in intact controls (0.215 g/cm2) at day 120. S-4 treatment either partially (i.e., BMD significantly greater than OVX controls) or fully (i.e., BMD not significantly different than intact controls) prevented the loss of skeletal BMD in OVX animals at doses greater than 0.1 mg/day. DHT fully maintained BMD in the OVX animals. However, in intact animals, DHT caused a significant decrease in BMD. S-4 treatment in intact animals maintained BMD at the level of intact controls. Co-administration of bicalutamide, a pure antiandrogen, partially prevented the effects of S-4, suggesting that the AR was important for regulating the bone response to the drug. Reference: Pharm Res. 2007 Feb; 24(2): 328–335. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2039878/

	Solvent	mg/mL	mM
Solubility
	DMSO	69.7	157.85
	DMSO:PBS (pH 7.2) (1:1)	0.5	1.13
	DMF	20.0	45.31
	Ethanol	51.5	116.68

Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 441.36 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:

1. Kearbey JD, Gao W, Narayanan R, Fisher SJ, Wu D, Miller DD, Dalton JT. Selective Androgen Receptor Modulator (SARM) treatment prevents bone loss and reduces body fat in ovariectomized rats. Pharm Res. 2007 Feb;24(2):328-35. doi: 10.1007/s11095-006-9152-9. Epub 2006 Oct 25. PMID: 17063395; PMCID: PMC2039878. 2. Gao W, Reiser PJ, Coss CC, Phelps MA, Kearbey JD, Miller DD, Dalton JT. Selective androgen receptor modulator treatment improves muscle strength and body composition and prevents bone loss in orchidectomized rats. Endocrinology. 2005 Nov;146(11):4887-97. doi: 10.1210/en.2005-0572. Epub 2005 Aug 11. PMID: 16099859; PMCID: PMC2039881.

In vitro protocol:

N/A

In vivo protocol:

1: Cawley AT, Smart C, Greer C, Liu Lau M, Keledjian J. Detection of the selective androgen receptor modulator andarine (S-4) in a routine equine blood doping control sample. Drug Test Anal. 2015 Oct 12. doi: 10.1002/dta.1867. [Epub ahead of print] PubMed PMID: 26456227. 2: Girgis CM, Mokbel N, Digirolamo DJ. Therapies for musculoskeletal disease: can we treat two birds with one stone? Curr Osteoporos Rep. 2014 Jun;12(2):142-53. doi: 10.1007/s11914-014-0204-5. Review. PubMed PMID: 24633910; PubMed Central PMCID: PMC4083371. 3: de Rijke E, Essers ML, Rijk JC, Thevis M, Bovee TF, van Ginkel LA, Sterk SS. Selective androgen receptor modulators: in vitro and in vivo metabolism and analysis. Food Addit Contam Part A Chem Anal Control Expo Risk Assess. 2013;30(9):1517-26. doi: 10.1080/19440049.2013.810346. Epub 2013 Jul 24. PubMed PMID: 23883284. 4: Starcevic B, Ahrens BD, Butch AW. Detection of the selective androgen receptor modulator S-4 (Andarine) in a doping control sample. Drug Test Anal. 2013 May;5(5):377-9. doi: 10.1002/dta.1466. Epub 2013 Feb 21. PubMed PMID: 23427117. 5: Thomas A, Geyer H, Schänzer W, Crone C, Kellmann M, Moehring T, Thevis M. Sensitive determination of prohibited drugs in dried blood spots (DBS) for doping controls by means of a benchtop quadrupole/Orbitrap mass spectrometer. Anal Bioanal Chem. 2012 May;403(5):1279-89. doi: 10.1007/s00216-011-5655-2. Epub 2012 Jan 10. PubMed PMID: 22231507. 6: Guddat S, Solymos E, Orlovius A, Thomas A, Sigmund G, Geyer H, Thevis M, Schänzer W. High-throughput screening for various classes of doping agents using a new 'dilute-and-shoot' liquid chromatography-tandem mass spectrometry multi-target approach. Drug Test Anal. 2011 Nov-Dec;3(11-12):836-50. doi: 10.1002/dta.372. Epub 2011 Dec 2. PubMed PMID: 22135086. 7: Grata E, Perrenoud L, Saugy M, Baume N. SARM-S4 and metabolites detection in sports drug testing: a case report. Forensic Sci Int. 2011 Dec 10;213(1-3):104-8. doi: 10.1016/j.forsciint.2011.07.014. Epub 2011 Aug 3. PubMed PMID: 21816554. 8: Thevis M, Thomas A, Möller I, Geyer H, Dalton JT, Schänzer W. Mass spectrometric characterization of urinary metabolites of the selective androgen receptor modulator S-22 to identify potential targets for routine doping controls. Rapid Commun Mass Spectrom. 2011 Aug 15;25(15):2187-95. doi: 10.1002/rcm.5100. PubMed PMID: 21710598. 9: Kohler M, Thomas A, Geyer H, Petrou M, Schänzer W, Thevis M. Confiscated black market products and nutritional supplements with non-approved ingredients analyzed in the Cologne Doping Control Laboratory 2009. Drug Test Anal. 2010 Nov-Dec;2(11-12):533-7. doi: 10.1002/dta.186. Epub 2010 Oct 26. Review. PubMed PMID: 21204286. 10: Thevis M, Thomas A, Fusshöller G, Beuck S, Geyer H, Schänzer W. Mass spectrometric characterization of urinary metabolites of the selective androgen receptor modulator andarine (S-4) for routine doping control purposes. Rapid Commun Mass Spectrom. 2010 Aug 15;24(15):2245-54. doi: 10.1002/rcm.4637. PubMed PMID: 20623476. 11: Jones A, Hwang DJ, Narayanan R, Miller DD, Dalton JT. Effects of a novel selective androgen receptor modulator on dexamethasone-induced and hypogonadism-induced muscle atrophy. Endocrinology. 2010 Aug;151(8):3706-19. doi: 10.1210/en.2010-0150. Epub 2010 Jun 9. PubMed PMID: 20534726. 12: Thevis M, Geyer H, Kamber M, Schänzer W. Detection of the arylpropionamide-derived selective androgen receptor modulator (SARM) S-4 (Andarine) in a black-market product. Drug Test Anal. 2009 Aug;1(8):387-92. doi: 10.1002/dta.91. PubMed PMID: 20355219. 13: Furuya K. [Bone and Men's Health. Bone selective androgen receptor modulators]. Clin Calcium. 2010 Feb;20(2):225-33. doi: CliCa1002225233. Review. Japanese. PubMed PMID: 20118515. 14: Kearbey JD, Gao W, Narayanan R, Fisher SJ, Wu D, Miller DD, Dalton JT. Selective Androgen Receptor Modulator (SARM) treatment prevents bone loss and reduces body fat in ovariectomized rats. Pharm Res. 2007 Feb;24(2):328-35. Epub 2006 Oct 25. PubMed PMID: 17063395; PubMed Central PMCID: PMC2039878. 15: Perera MA, Yin D, Wu D, Chan KK, Miller DD, Dalton J. In vivo metabolism and final disposition of a novel nonsteroidal androgen in rats and dogs. Drug Metab Dispos. 2006 Oct;34(10):1713-21. Epub 2006 Jun 30. PubMed PMID: 16815963. 16: Gao W, Reiser PJ, Coss CC, Phelps MA, Kearbey JD, Miller DD, Dalton JT. Selective androgen receptor modulator treatment improves muscle strength and body composition and prevents bone loss in orchidectomized rats. Endocrinology. 2005 Nov;146(11):4887-97. Epub 2005 Aug 11. PubMed PMID: 16099859; PubMed Central PMCID: PMC2039881. 17: Kearbey JD, Wu D, Gao W, Miller DD, Dalton JT. Pharmacokinetics of S-3-(4-acetylamino-phenoxy)-2-hydroxy-2-methyl-N-(4-nitro- 3-trifluoromethyl-phenyl)-propionamide in rats, a non-steroidal selective androgen receptor modulator. Xenobiotica. 2004 Mar;34(3):273-80. PubMed PMID: 15204699; PubMed Central PMCID: PMC2040234.